HR Execs on the Move

Parsley Health

www.parsleyhealth.com

 
Parsley Health is a new kind of healthcare service that integrates technology, nutrition, wellness and prevention into cutting-edge primary care.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Stephanie Fogle
SVP, People and Culture Profile
Barb Chang
SVP of Product Profile
Patty Izquierdo
Senior Director of People Profile
Robin Berzin
Founder and Chief Executive Officer Profile

Similar Companies

Alaska Native Tribal Health Consortium

The Alaska Native Tribal Health Consortium is a not-for-profit tribal health organization managed by Alaska Native tribal governments and their regional health organizations.

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.

AGENIXS

Agenixs creates change in the world by elevating people to healthier, longer, and more fulfilling lives, empowering each on their own journey of changing the world.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.

Three Rivers Pathology

Three Rivers Pathology is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.